Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes - Radioactive & Nonradioactive

V-48 labeled VO(acac)2for hybrid PET/MR imaging of cancer

Brittany Broder, Mohammed Bhuiyan, Richard Freifelder, Anna Kucharski, Lara Leoni, Hsiu-Ming Tsai, Hannah Zhang, Devkumar Mustafi, Marvin Makinen, Gregory Karczmar, Chien-Min Kao and Chin-Tu Chen
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1176;
Brittany Broder
1University of Chicago Chicago IL United States
2University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammed Bhuiyan
1University of Chicago Chicago IL United States
2University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Freifelder
1University of Chicago Chicago IL United States
2University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Kucharski
1University of Chicago Chicago IL United States
2University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lara Leoni
1University of Chicago Chicago IL United States
2University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hsiu-Ming Tsai
1University of Chicago Chicago IL United States
2University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hannah Zhang
1University of Chicago Chicago IL United States
2University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Devkumar Mustafi
1University of Chicago Chicago IL United States
2University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marvin Makinen
1University of Chicago Chicago IL United States
2University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory Karczmar
1University of Chicago Chicago IL United States
2University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chien-Min Kao
1University of Chicago Chicago IL United States
2University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chin-Tu Chen
1University of Chicago Chicago IL United States
2University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

1176

Objectives: We previously demonstrated the use of vanadyl (VO2+) chelate bis(acetylacetonato) oxovanadium(IV) [VO(acac)2] as an effective contrast agent in magnetic resonance imaging (MRI) for potential early detection and staging of cancer, such as in mouse models of colorectal cancer (CRC) [1,2]. Previous studies showed increased tumor uptake of 48V-VO(acac)2 in PET (positron emission tomography) imaging in CRC [3]. Our current research is extended to development of dual-modality PET/MR imaging using 48V labeled VO(acac)2 for improved imaging in cancer detection and staging. We report our progress on improving the cyclotron production of 48V, optimizing the synthesis of 48V-VO(acac)2, decreasing radiotracer impurities, and validating the utility of this new radiotracer in PET/MR studies of CRC in mouse models. Methods: Two thin natural titanium foils were irradiated via the 48Ti(p,n)48V reaction at 40 µA until an optimal activity was obtained. The foil was left to decay overnight to mitigate short-lived isotopes. The target was dissolved in HF and H2SO4 (4:1) and 48V was isolated in a series of radiochemical steps before being complexed with acetyl acetone under reflux to form 48V-VO(acac)2. The solution was passed through an OnGuard II M cartridge (Thermo Fisher Scientific), used to concentrate free transition metals, to separate 48V-VO(acac)2 from free vanadium, which does not target the same metabolic pathways and decreases image quality. The purity of the resulting radiotracer was assessed using aluminum-backed thin layer chromatography (TLC). Two drops of the sample were placed 1 cm from the plate edge. The plate was developed in MeOH and H2O (99:1) and evaluated using a TLC imaging scanner (Mini-Scan, Eckert & Ziegler): chelated and free vanadium were expected to separate due to their chemical state. Once purity was established, the radiotracer was validated in PET/MR studies by demonstrating uptake in a xenograph mouse model of CRC. Mice were imaged over 30 minutes in an MRI scanner with a PET-insert. The results were confirmed with separate PET and MR imaging studies. In-vivo biodistribution studies were performed 48 hours post injection. Results: Two thin 12 µm natural titanium foils (13 mg together) were irradiated for 33 hours amounting to 1323µA[asterisk]h, yielding 17.8 mCi which decayed to 11.65 mCi by the beginning of isolation. Both foils were dissolved in 400 µL HF and 100 µL H2SO4. After heating under argon flow, 10.6 mCi were transferred to a platinum crucible, neutralized, and oxidized at 790°C with a mixture of Na2CO3 and NaNO3 (43:1). Once cooled, 7.5 mCi were centrifuged for 10 minutes at 5000 rpm. The 7 mCi supernatant was pH adjusted to 3-4 with HCl. The solution was passed through a Chelex-100 column which was then eluted with NH3, yielding 3.8 mCi as NH4VO3. The solvent was dried at 300°C before 1.3 mCi was combined with acetyl acetonate and heated under reflux. The resulting 182 µCi of 48V-VO(acac)2 was passed through an OnGuard II M filter, which trapped free vanadium and passed 48V-VO(acac)2, yielding 85 µCi. The composition of the eluent was assessed twice with TLC, showing high counts of 48V-VO(acac)2. Uptake of 48V-VO(acac)2 was validated in PET/MR imaging experiments. The biodistribution was followed two days post injection and confirmed the uptake of the radiotracer in respective organs and tumor. Conclusion: This experiment yielded a workable geometry for foil irradiation given the activity produced. Despite low synthesis yields, several steps were identified for improvement. Further investigation found that additional steps should be taken when chelated compounds are present using the OnGuard II M cartridge; forgoing these steps results in a smearing of yellow iron in the cartridge, which was observed. The counts of free vanadium indicate the filtration was not completely successful; the additional procedure could produce higher yields. PET/MR imaging validated the increased uptake of this novel radiotracer for potentially improving early cancer detection.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 60, Issue supplement 1
May 1, 2019
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
V-48 labeled VO(acac)2for hybrid PET/MR imaging of cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
V-48 labeled VO(acac)2for hybrid PET/MR imaging of cancer
Brittany Broder, Mohammed Bhuiyan, Richard Freifelder, Anna Kucharski, Lara Leoni, Hsiu-Ming Tsai, Hannah Zhang, Devkumar Mustafi, Marvin Makinen, Gregory Karczmar, Chien-Min Kao, Chin-Tu Chen
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1176;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
V-48 labeled VO(acac)2for hybrid PET/MR imaging of cancer
Brittany Broder, Mohammed Bhuiyan, Richard Freifelder, Anna Kucharski, Lara Leoni, Hsiu-Ming Tsai, Hannah Zhang, Devkumar Mustafi, Marvin Makinen, Gregory Karczmar, Chien-Min Kao, Chin-Tu Chen
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1176;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes - Radioactive & Nonradioactive

  • Relationships between tau, atrophy, regional brain activity and connectivity in Alzheimer's disease: a PET/MRI multimodal study
  • Gray matter structural networks related to 18F-THK5351 retention in cognitively normal older adults and early Alzheimer’s disease patients
  • Assessment of α4β2 nicotinic acetylcholine receptor (nAChR) availability and neuronal response to rewarding food-cues in human obesity using simultaneous PET-MRI
Show more Molecular Targeting Probes - Radioactive & Nonradioactive

Novel Multimodality and Nonradioactive Probes Posters

  • Indocyanine Green Derived Dual-modality Agent for Imaging-guided Therapy of Hepatocellular Carcinomas
  • A targeted high-Z nanoparticles designed for external radiotherapy sensitization of solid tumor in vivo
  • TEMPO Compounds for PET/MRI Imaging of Oxidative Stress
Show more Novel Multimodality and Nonradioactive Probes Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire